Skip to main content
ZHEJIANG INT’L GROUP CO.,LTD. logo

ZHEJIANG INT’L GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 000411 ISIN · CNE0000008D9 LEI · 300300ZQI0D30GMZC758 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 2,219 across all filing types
Latest filing 2026-05-07 Investor Presentation
Country CN China
Listing Shenzhen Stock Exchange 000411

About ZHEJIANG INT’L GROUP CO.,LTD.

https://www.intmedic.com

ZHEJIANG INT’L GROUP CO.,LTD. specializes in the distribution and supply chain management of pharmaceutical products and medical equipment. The company operates an extensive network for the wholesale and retail of western medicines, traditional Chinese medicines, and biological products. It provides integrated logistics services, including specialized cold chain management and warehousing, to healthcare institutions and retail pharmacies. The group also engages in the import and export of medical supplies and health-related commodities. By utilizing advanced information technology and a robust logistics infrastructure, the company optimizes the healthcare supply chain to ensure the efficient delivery of essential medical resources to its diverse customer base.

Recent filings

Filing Released Lang Actions
关于参加浙江辖区上市公司2026年投资者网上集体接待日暨2025年度业绩说明会的公告
Investor Presentation Classification · 85% confidence The document is an announcement about the company's participation in an investor online collective reception day and a 2025 annual performance explanation meeting. It describes the event details, including date, time, and how investors can participate and submit questions. It does not contain actual financial statements or detailed financial data, nor is it a transcript or report itself. The document is essentially an announcement of an upcoming investor presentation or meeting focused on discussing the annual results and other company matters. Given the nature of the content, it fits best as an Investor Presentation (IP) announcement or invitation rather than the report itself. However, since it is announcing the event and inviting participation rather than providing the presentation materials, it aligns most closely with the Investor Presentation (IP) category, which includes detailed presentations for investors focusing on financials, strategy, and market position. The document is not short enough or phrased as a report publication announcement (RPA), nor is it a regulatory filing or other category. Therefore, the best classification is Investor Presentation (IP).
2026-05-07 Chinese
2025年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year 2025, issued by the company's board. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2025, including financial and non-financial internal control deficiencies, evaluation scope, standards, and remediation status. The content is detailed and substantive, focusing on internal control evaluation rather than financial results or audit opinions alone. It is not an Annual Report (10-K), Audit Report (AR), or Interim Report (IR) since it specifically addresses internal control evaluation. It is not a short announcement or certification but a full report on internal control evaluation. This type of document aligns best with the Audit Report / Information (AR) category, which includes audit reports and internal control evaluation results. The document length (4581 characters) is sufficient to be considered a report rather than a brief announcement. Therefore, the classification is AR with high confidence.
2026-04-22 Chinese
关于英特药业为英特海斯医药和绍兴英特大通提供财务资助的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhejiang Yingte Group Co., Ltd. regarding financial assistance provided by its subsidiary Yingte Pharmaceutical to its controlled subsidiaries Yingte Hais Pharmaceutical and Shaoxing Yingte Datong Pharmaceutical. It details the amounts, terms, and conditions of the financial support, including board approval and shareholder meeting requirements. The document is structured as a formal announcement with financial data summaries but does not contain comprehensive financial statements or detailed financial analysis typical of an interim or annual report. It is not a full financial report but rather a disclosure about financing activities within the group. The document length is 3860 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2026-04-22 Chinese
董事会关于独立董事独立性自查情况的专项报告
Governance Information Classification · 95% confidence The document is a special report from the board of directors regarding the independence of the company's independent directors. It references regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange rules about independent directors' independence. The content focuses on governance and compliance with independence standards for board members. It does not contain financial data, earnings, or audit information, nor is it an announcement of voting results or a meeting. This fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is short but contains substantive governance content, not just an announcement or certification, so it is not RNS or RPA.
2026-04-22 Chinese
2025年年度审计报告
Regulatory Filings
2026-04-22 Chinese
天健会计师事务所（特殊普通合伙）关于浙江英特药业有限责任公司业绩承诺期届满之标的资产减值测试审核报告
Regulatory Filings
2026-04-22 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.